Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. May 20, 2022; 12(3): 107-112
Published online May 20, 2022. doi: 10.5662/wjm.v12.i3.107
Published online May 20, 2022. doi: 10.5662/wjm.v12.i3.107
Lutetium in prostate cancer: Reconstruction of patient-level data from published trials and generation of a multi-trial Kaplan-Meier curve
Andrea Messori, Department of HTA, ESTAR Toscana and Regione Toscana, Firenze 50139, Italy
Author contributions: Messori A is the sole author, read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrea Messori, PharmD, Senior Researcher, Department of HTA, ESTAR Toscana and Regione Toscana, via Alderotti 26/N, Firenze 50139, Italy. andrea.messori.it@gmail.com
Received: October 26, 2021
Peer-review started: October 26, 2021
First decision: December 17, 2021
Revised: December 18, 2021
Accepted: March 16, 2021
Article in press: March 16, 2021
Published online: May 20, 2022
Peer-review started: October 26, 2021
First decision: December 17, 2021
Revised: December 18, 2021
Accepted: March 16, 2021
Article in press: March 16, 2021
Published online: May 20, 2022
Core Tip
Core Tip: This paper describes the application of a new technique of individual-patient data reconstruction to the progression-free survival curves published in two trials evaluating lutetium in metastatic prostate cancer. Our analysis interpreted these survival data and showed discordant results between the two trials, that need to be addressed by further clinical research.